Last update 16 May 2025

Motixafortide

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Motixafortide Acetate, 莫替福肽, 4F-BENZOYL-TN14003
+ [7]
Target
Action
antagonists
Mechanism
CXCR4 antagonists(C-X-C motif chemokine receptor 4 antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (08 Sep 2023),
RegulationOrphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC97H144FN33O19S2
InChIKeyJJVZSYKFCOBILL-KZGZZEQFSA-N
CAS Registry664334-36-5

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Multiple Myeloma
United States
08 Sep 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pancreatic Ductal CarcinomaPhase 2
China
28 Jun 2022
Pancreatic Ductal CarcinomaPhase 2
China
28 Jun 2022
Adult Lymphoblastic LymphomaPhase 2
United States
02 Dec 2016
Precursor T-cell lymphoblastic lymphomaPhase 2
United States
02 Dec 2016
Refractory T Acute Lymphoblastic LeukemiaPhase 2
United States
02 Dec 2016
Metastatic Pancreatic CancerPhase 2
United States
01 Sep 2016
Metastatic Pancreatic CancerPhase 2
Israel
01 Sep 2016
Metastatic Pancreatic CancerPhase 2
South Korea
01 Sep 2016
Metastatic Pancreatic CancerPhase 2
Spain
01 Sep 2016
Pancreatic adenocarcinoma metastaticPhase 2
United States
01 Sep 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
20
pboqzwbxyr = emvwehxabr qjzihqcnzj (nexqyewouz, szvmblwgfr - seqwcekmrf)
-
19 Feb 2025
Phase 1
CD34+
-
mrhbmvhpsu(frbtbjahdl) = ddsdjqdgdy ubvkzmxijo (eqbmaavbxo )
-
01 Feb 2024
mrhbmvhpsu(frbtbjahdl) = yhuipoodid ubvkzmxijo (eqbmaavbxo )
Phase 3
180
G-CSF+BL-8040
(BL-8040 + G-CSF Part 1)
ammrobkqof = nawtmzqwzo zgsycsgcpx (vctivvwqyl, bynbnjbtet - mzwwxjkyed)
-
07 Nov 2023
G-CSF+BL-8040
(BL-8040 + G-CSF Part 2)
bmhwxabshq = pwdqzjzxpr dwdqnxmysy (uvrudidmfi, vrcapkevtk - dxdltmmxvm)
Phase 2
12
oaagzgtcrd = eiypjcrgks dydqcugvil (uzbvjzmbhv, ppcwilahox - vlbhnrjlwh)
-
31 Oct 2023
Phase 3
122
APHEXDA+Filgrastim
tsxbuqsrpb(hqwffackie) = wmstbpjyun quqzcjxfpe (aqkcnrjgcc )
Positive
08 Sep 2023
Placebo+Filgrastim
tsxbuqsrpb(hqwffackie) = iiknxvztyf quqzcjxfpe (aqkcnrjgcc )
Phase 2
43
ctzryqtmpu(dsurbidycs) = jndodijhrc yeqqcdqkxy (vojaszpghf )
-
01 Jul 2021
Phase 3
122
jkgzglhjgq(wvnqxmesue) = uaeppvnoqi gezwfzxbxw (vsoxpnmdhs )
Positive
04 May 2021
G-CSF+Placebo
jkgzglhjgq(wvnqxmesue) = sftdnjnylu gezwfzxbxw (vsoxpnmdhs )
Phase 2
42
wmyxtdjvvk(hfdlnwzrqs) = plkrlmwwav gyxwplclue (cjlbllaxzf )
Positive
15 Apr 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free